NCT05275777进行中（未招募）1 期
A Phase Ib Safety lead-in, Followed by Phase II Trial of ADG106 in Combination With Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel in Stage I-III HER2 Negative Breast Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 66
- 试验地点
- 1
- 主要终点
- Number of participant with treatment related toxicities
研究概览
简要总结
This is an open label, lead in phase Ib dose confirmation study in patients with advanced solid tumors, followed by a phase II single arm study as neoadjuvant therapy in stage I-III HER2 negative breast cancer.
Primary Objectives
- To determine the safety profile of combination of ADG106 with dose dense doxorubicin/cyclophosphamide, and with weekly paclitaxel.
- To determine the Recommended Phase 2 Dose (RP2D) of ADG106 in combination with dose dense doxorubicin/cyclophosphamide, and with weekly paclitaxel.
- To evaluate biological changes on immunohistochemistry in HER2 negative breast cancer after treatment with ADG106 alone and in combination with chemotherapy.
Secondary Objectives
- To determine the efficacy of combination of ADG106 with standard neoadjuvant combination chemotherapy in HER2 negative breast cancer: objective response rates.
- To correlate tumor and plasma biomarkers with efficacy outcomes.
详细描述
The phase Ib segment will be carried out with a standard 3+3 dose de-escalation design. Patients with advanced/ metastatic solid organ cancers will be enrolled in 2 parallel cohorts.
Cohort 1 will receive ADG106 in combination with dose dense doxorubicin/ cyclophosphamide (AC).
Cohort 2 will receive ADG106 in combination with weekly paclitaxel.
In the phase II portion, patients with stage I-III HER2 negative breast cancer planned for neoadjuvant chemotherapy will be enrolled. Patients will be treated with neoadjuvant chemotherapy (ddAC followed by paclitaxel for 12 weeks) combined with ADG106, before definitive breast cancer surgery
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 99 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients may be included in the study only if they meet all of the following criteria:
- •All patients must sign an informed consent in accordance with local institutional guidelines.
- •18 years and above of age.
- •Estimated life expectancy of at least 12 weeks.
- •Has recovered from acute toxicities from prior anti-cancer therapies (phase Ib).
- •a) Phase Ib: Patients with histologically or cytologically confirmed advanced or metastatic solid tumors who have radiological evidence of progressive disease on study entry that are deemed likely to benefit from either dose dense doxorubicin/ cyclophosphamide or weekly paclitaxel.
- •There is no upper limit on the number of prior treatments provided all inclusion/ exclusion criteria are met. Hormone ablation therapy is considered an anti-cancer regimen. Radiation therapy and surgery are not considered anti-cancer regimens.
- •Prior receipt of immunotherapy is allowed. b) Phase II: Untreated stage I-III HER2 negative breast cancer patients who are planned for neoadjuvant chemotherapy followed by definitive breast cancer surgery.
- •Measurable disease by RECIST 1.1 criteria.
- •Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-
- •Left ventricular ejection fraction of ≥ 50% for Cohort 1 in phase Ib and all patients in phase II.
- •Adequate bone marrow function and organ function within 2 weeks of study treatment.
- •Adequate hematologic function defined as:
- •Absolute neutrophil count (ANC) ≥ 1.5 x 109/L
- •Platelets ≥ 100 x 109/L
- •Hemoglobin ≥ 9 x 109/L
- •Adequate hepatic function defined as:
- •Bilirubin < 1.5 times the upper limit of normal (ULN)
- •ALT or AST < 2.5 times ULN (or < 5 times ULN with presence of liver metastases)
- •Adequate renal function defined as:
- •Calculated creatinine clearance of ≥ 60 mL/min, calculated using the formula of Cockroft and Gault: (140-Age) x Mass (kg)/(72 x creatinine mg/dL); multiply by 0.85 if female.
- •Adequate coagulation function defined as:
- •Activated partial thromboplastin time (aPTT) ≤1.5 x ULN
- •International normalized ratio (INR) ≤1.5 x ULN (Exception: INR 2 to ≤3 x ULN is acceptable for patients on warfarin anticoagulation
- •Patients with reproductive potential must use an approved contraceptive method if appropriate (e.g., intrauterine device, birth control pills, or barrier device) during and for three months after the study. Females with childbearing potential must have a negative serum pregnancy test within 7 days prior to study enrolment.
- •Able to comply with study related procedures.
排除标准
- •Patients will be excluded from the study for any of the following reasons:
- •Treatment within the last 30 days with any investigational drug.
- •Concurrent administration of any other tumor therapy, including cytotoxic chemotherapy, hormonal therapy, and immunotherapy.
- •Major surgery within 28 days of study drug administration.
- •Active infection that in the opinion of the investigator would compromise the patient's ability to tolerate therapy.
- •Serious concomitant disorders that would compromise the safety of the patient or compromise the patient's ability to complete the study, at the discretion of the investigator.
- •Active, known or suspected autoimmune disease. Subjects with type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enrol.
- •Subjects with a condition requiring systemic treatment with either corticosteroids (>10mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of randomization. Inhaled or topical steroids, and adrenal replacement steroid >10mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease.
- •Subjects with interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicity.
- •Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS).
- •Active hepatitis B (positive hepatitis B surface antigen [HBsAg]) or HCV (hepatitis C virus) [positive HCV RNA])
- •Patients with past HBV infection or resolved HBV infection (defined as the presence of hepatitis B core antibody [HBcAb] and absence of HBsAg) are eligible. HBV DNA must be obtained in these patients prior to randomization. HBV carriers or those patients requiring antiviral therapy are not eligible to participate.
- •Patients positive for HCV antibody are eligible only if PCR is negative for HCV RNA.
- •HBV carriers or those subjects receiving antiviral treatment of hepatitis B virus or Hepatitis C are not eligible.
- •Breast feeding.
- •Second primary malignancy that is clinically detectable at the time of consideration for study enrolment. The exception is patients in phase II with two or more primary invasive breast cancers that are both HER2 negative and where both cancers are amenable to repeated biopsy. In this case, each tumor will be biopsied and assessed separately for treatment response.
- •Symptomatic brain metastases.
- •History of significant neurological or mental disorder, including seizures or dementia.
- •Unable to comply with study procedures.
- •Phase II cohort: Prior treatment for locally advanced or metastatic breast cancer.
- •Patients with known underlying hemoglobinopathies (e.g., thalassemia). Note: patients without known hemoglobinopathies do not specifically need to be screened for hemoglobinopathies in the absence of clinical suspicion).
- •History of life-threatening hypersensitivity or known to be allergic to protein drugs or recombinant proteins or any ingredients contained in the ADG106 drug formulation (succinic acid, arginine, polysorbate 80 and hydrochloric acid).
- •Peripheral neuropathy grade ≥
- •Live viral vaccine therapies within 4 weeks prior to the first dose of study drug.
研究组 & 干预措施
ADG106 combined with dose dense Doxorubicin and Cyclophosphamide (Phase Ib)
Experimental
Intravenous ADG106 + 2 weekly doxorubicin and cyclophosphamide
干预措施: ADG106 (Drug)
ADG106 combined with dose dense Doxorubicin and Cyclophosphamide (Phase Ib)
Experimental
Intravenous ADG106 + 2 weekly doxorubicin and cyclophosphamide
干预措施: Doxorubicin (Drug)
ADG106 combined with dose dense Doxorubicin and Cyclophosphamide (Phase Ib)
Experimental
Intravenous ADG106 + 2 weekly doxorubicin and cyclophosphamide
干预措施: Cyclophosphamide (Drug)
ADG106 combined with Paclitaxel (Phase Ib)
Experimental
Intravenous ADG106 + weekly paclitaxel
干预措施: ADG106 (Drug)
ADG106 combined with Paclitaxel (Phase Ib)
Experimental
Intravenous ADG106 + weekly paclitaxel
干预措施: Paclitaxel (Drug)
ADG106 combined with dose dense Doxorubicin and Cyclophosphamide follow by Paclitaxel (Phase II)
Experimental
Intravenous ADG106 combined with two weekly doxorubicin and cyclophosphamide followed intravenous ADG106 combined with weekly paclitaxel
干预措施: ADG106 (Drug)
ADG106 combined with dose dense Doxorubicin and Cyclophosphamide follow by Paclitaxel (Phase II)
Experimental
Intravenous ADG106 combined with two weekly doxorubicin and cyclophosphamide followed intravenous ADG106 combined with weekly paclitaxel
干预措施: Doxorubicin (Drug)
ADG106 combined with dose dense Doxorubicin and Cyclophosphamide follow by Paclitaxel (Phase II)
Experimental
Intravenous ADG106 combined with two weekly doxorubicin and cyclophosphamide followed intravenous ADG106 combined with weekly paclitaxel
干预措施: Cyclophosphamide (Drug)
ADG106 combined with dose dense Doxorubicin and Cyclophosphamide follow by Paclitaxel (Phase II)
Experimental
Intravenous ADG106 combined with two weekly doxorubicin and cyclophosphamide followed intravenous ADG106 combined with weekly paclitaxel
干预措施: Paclitaxel (Drug)
结局指标
主要结局
Number of participant with treatment related toxicities
时间窗: From enrolment till 30 days after last dose of study treatment
Toxicities will be graded using the Common Terminology Criteria for Adverse Events (CTCAE) toxicity grading version 5.0.
Histological response after neoadjuvant ADG106 + chemotherapy
时间窗: After 20 weeks of neoadjuvant chemotherapy
Biological changes on immunohistochemistry will be evaluated using paraffin-embedded tumor specimens.
次要结局
- Objective response rate in Phase Ib(At the end of every 3 cycles up to 24 weeks, at the end of every 6 cycles after 24 weeks up to 60 weeks (each cycle is 2 weeks))
- Overall survival in Phase Ib(From enrolment till date of death or final follow up visit (maximum 1 year after last treatment dose))
- Correlation of plasma biomarkers with efficacy outcome in Phase Ib(baseline, at the end of week 1, 2, 4, 6, 8, 10, 12, 14, 18, 30, 42, 54, 66)
- Progression free survival in Phase Ib(From enrolment till disease progression or date of death or final follow-up visit (maximum 1 year after last treatment dose).)
- Clinical response rate in Phase II(baseline, at the end of 2 weeks, 4 weeks, 8 weeks, 10 weeks, 12 weeks of treatment.)
- Pathological complete response rate in Phase II(after 20 weeks neoadjuvant chemotherapy)
- Relapse free survival in Phase II(From enrolment to final follow up visit (maximum 6 years from last treatment dose))
研究者
研究点 (1)
Loading locations...
相似试验
终止
1 期
Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206)Solid TumorsAdvanced MalignanciesMetastatic CancerNCT02959437Incyte Corporation70
终止
1 期
An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced MalignanciesSolid TumorsAdvanced MalignanciesMetastatic CancerNCT02265510Incyte Corporation83
已完成
1 期
Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast CancerHER2-Positive Metastatic Breast CancerHER2-Negative Metastatic Breast CancerLocally Advanced or Early Breast CancerNCT02605915Hoffmann-La Roche98
已完成
1 期
A Phase 1b/2 Study of ADG116, ADG116 Combined With Anti-PD-1 Antibody or Anti-CD137 Antibody in Solid Tumors PatientsAdvanced/Metastatic Solid TumorsNCT04501276Adagene Inc72
Unknown
1 期
Phase Ib/II Clinical Study of Pexa-Vec (Vaccinia GM CSF / Thymidine Kinase-Deactivated Virus) Combined With Recombinant Whole Human Anti-PD-L1 Monoclonal Antibody (ZKAB001) in Metastatic MelanomaLocal Progression or Metastatic Melanoma With Failed First-line TreatmentNCT04849260Lee's Pharmaceutical Limited54